HC Wainwright Reaffirms “Neutral” Rating for Zura Bio (NASDAQ:ZURA)

HC Wainwright reiterated their neutral rating on shares of Zura Bio (NASDAQ:ZURA) in a research note issued to investors on Monday, Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock.

A number of other research analysts have also weighed in on the stock. Piper Sandler reissued an “overweight” rating and issued a $26.00 target price on shares of Zura Bio in a report on Thursday, September 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zura Bio in a research note on Friday, October 18th.

Zura Bio Price Performance

ZURA opened at $4.64 on Monday. The firm has a 50-day simple moving average of $3.98 and a two-hundred day simple moving average of $3.99. Zura Bio has a 52 week low of $2.00 and a 52 week high of $6.35.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.02). As a group, equities research analysts anticipate that Zura Bio will post -0.47 EPS for the current fiscal year.

Insider Activity at Zura Bio

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the business’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $3.87, for a total transaction of $200,187.36. Following the transaction, the director now owns 2,085,418 shares in the company, valued at $8,070,567.66. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 15.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Zura Bio

Several hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC bought a new stake in Zura Bio in the second quarter worth about $43,000. SG Americas Securities LLC bought a new stake in shares of Zura Bio during the 3rd quarter worth approximately $62,000. Renaissance Technologies LLC lifted its stake in shares of Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after acquiring an additional 5,900 shares during the last quarter. Forefront Analytics LLC boosted its holdings in Zura Bio by 22.1% during the 2nd quarter. Forefront Analytics LLC now owns 41,569 shares of the company’s stock valued at $145,000 after acquiring an additional 7,531 shares during the period. Finally, Bank of New York Mellon Corp grew its position in Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after acquiring an additional 6,412 shares during the last quarter. 61.14% of the stock is currently owned by institutional investors.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.